Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Prospective Trial of Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (CRPC) Patients Progressing on Enzalutamide

NCT02685267 is registered in ClinicalTrials.gov with Prostate Cancer Clinical Trials Consortium as lead sponsor.

NCT NCT02685267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02685267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Prospective Trial of Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (CRPC) Patients Progressing on Enzalutamide
Lead sponsor
Prostate Cancer Clinical Trials Consortium
Phase
Phase 2
Overall status
Terminated
Start date
February 29, 2016
Completion date
August 31, 2017
Enrollment
9 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer